Wasatch Advisors Inc. decreased its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 5.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 713,404 shares of the biopharmaceutical company’s stock after selling 42,311 shares during the period. Wasatch Advisors Inc. owned about 2.78% of Esperion Therapeutics worth $35,756,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. US Bancorp DE increased its holdings in shares of Esperion Therapeutics by 1.1% in the 2nd quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 104 shares in the last quarter. Voya Investment Management LLC increased its holdings in shares of Esperion Therapeutics by 12.7% in the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 806 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of Esperion Therapeutics by 3.0% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after purchasing an additional 1,148 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Esperion Therapeutics by 5.3% in the 2nd quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Esperion Therapeutics by 3.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 50,420 shares of the biopharmaceutical company’s stock worth $2,333,000 after purchasing an additional 1,658 shares in the last quarter. 93.15% of the stock is owned by institutional investors and hedge funds.

WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/22/esperion-therapeutics-inc-espr-shares-sold-by-wasatch-advisors-inc.html.

Shares of Esperion Therapeutics, Inc. (ESPR) traded up $0.95 on Wednesday, hitting $56.53. The company had a trading volume of 134,222 shares, compared to its average volume of 1,045,121. Esperion Therapeutics, Inc. has a one year low of $10.30 and a one year high of $57.67.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period in the prior year, the company earned ($0.77) earnings per share. analysts forecast that Esperion Therapeutics, Inc. will post -7.21 EPS for the current fiscal year.

A number of analysts have commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Bank of America Corporation reissued a “neutral” rating and issued a $60.00 target price on shares of Esperion Therapeutics in a report on Friday, August 11th. Northland Securities reissued a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Jefferies Group LLC raised Esperion Therapeutics from a “hold” rating to a “buy” rating and reduced their target price for the stock from $85.00 to $55.00 in a report on Tuesday, August 8th. Finally, Deutsche Bank AG set a $64.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Esperion Therapeutics has a consensus rating of “Buy” and a consensus target price of $58.92.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.